Trial · NCT03277690
Adverse events231
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
181 to 200 of 231
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Polymenorrhoea | Reproductive system and breast disorders | Levoketoconazole-ITT RW Phase | 0 | 22 | |
| other | Polymenorrhoea | Reproductive system and breast disorders | Placebo- ITT RW Phase | 0 | 22 | |
| other | Polymenorrhoea | Reproductive system and breast disorders | Safety Population | 4 | 84 | |
| serious | Hypokalemia | Metabolism and nutrition disorders | Levoketoconazole-ITT RW Phase | 1 | 22 | |
| serious | Hypokalemia | Metabolism and nutrition disorders | Placebo- ITT RW Phase | 0 | 22 | |
| serious | Hypokalemia | Metabolism and nutrition disorders | Safety Population | 3 | 84 | |
| serious | Limb Injury | Injury, poisoning and procedural complications | Levoketoconazole-ITT RW Phase | 0 | 22 | |
| serious | Limb Injury | Injury, poisoning and procedural complications | Placebo- ITT RW Phase | 0 | 22 | |
| serious | Limb Injury | Injury, poisoning and procedural complications | Safety Population | 1 | 84 | |
| serious | Hepatic enzyme increased | Investigations | Levoketoconazole-ITT RW Phase | 0 | 22 | |
| serious | Hepatic enzyme increased | Investigations | Placebo- ITT RW Phase | 0 | 22 | |
| serious | Hepatic enzyme increased | Investigations | Safety Population | 1 | 84 | |
| serious | Myocardial infarction | Cardiac disorders | Levoketoconazole-ITT RW Phase | 0 | 22 | |
| serious | Myocardial infarction | Cardiac disorders | Placebo- ITT RW Phase | 0 | 22 | |
| serious | Myocardial infarction | Cardiac disorders | Safety Population | 1 | 84 | |
| serious | Epistaxis | Respiratory, thoracic and mediastinal disorders | Levoketoconazole-ITT RW Phase | 0 | 22 | |
| serious | Epistaxis | Respiratory, thoracic and mediastinal disorders | Placebo- ITT RW Phase | 0 | 22 | |
| serious | Epistaxis | Respiratory, thoracic and mediastinal disorders | Safety Population | 1 | 84 | |
| serious | Fatigue | General disorders | Levoketoconazole-ITT RW Phase | 0 | 22 | |
| serious | Fatigue | General disorders | Placebo- ITT RW Phase | 0 | 22 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03277690/events?page=10